🧠 A new treatment for leptomeningeal metastases offers real hope for advanced-stage cancer patients.
A groundbreaking study published in Nature Medicine and presented at ASCO 2025 shows promising clinical results for patients with neurological metastases – primarily from breast and lung cancers.
💊 What is HER3-DXd?
HER3-DXd is an antibody-drug conjugate (ADC) targeting the HER3 receptor, which is often found in advanced cancer tumors.
The drug delivers a chemotherapy agent directly to the cancer cell – in a precise and targeted manner, with minimal damage to healthy tissues.
📈 TUXEDO-3 Study Results:
The study included patients with leptomeningeal disease (LMD), a condition previously considered nearly untreatable.
Highlights of the results:
– 65% of patients survived at least 3 months – a significant outcome for this population.
– Neurological function and quality of life were maintained or even improved.
– Side effects included anemia, nausea, and neutropenia – but no new brain toxicities were observed.
🌍 Why is this important?
CNS metastases are among the most difficult to treat. HER3-DXd offers, for the first time, a new treatment option for leptomeningeal metastases, with reasonable safety and promising efficacy – even in cases once deemed terminal.
🔗 Full study link:
https://www.nature.com/articles/s41591-025-03744-1
🧭 Looking for hope?
At Trial-In Pharma, we specialize in locating and accessing innovative cancer treatments – from around the world, personalized and without geographic limitations.
📩 Contact us for more information.
